

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
**WO 01/46463 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number: PCT/EP00/12996

(22) International Filing Date:  
20 December 2000 (20.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
A 2170/99 22 December 1999 (22.12.1999) AT

(71) Applicant: BAXTER AKTIENGESELLSCHAFT  
[AT/AT]; Industriestrasse 67, A-1221 Vienna (AT).

(72) Inventors: ZIMMERMANN, Klaus; Harlacherweg  
2/2/19, A-1220 Vienna (AT). TURECEK, Peter; Haupt-  
strasse 59g, Weidling, A-3400 Klosterneuburg (AT).  
SCHWARZ, Hans-Peter; Schindlergasse 32, A-1180  
Vienna (AT). RIEGER, Manfred; Dr. Nemecgasse 1/1/6,  
A-2230 Gänserndorf (AT).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished  
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE PREPARATION AND USE OF INTERNAL STANDARDS FOR NUCLEIC ACID AMPLIFI-  
CATION ASSAYS

(57) Abstract: Internal nucleic acid standards for nucleic acid amplification assays are provided. Specifically, internal nucleic acid standards are provided that are prepared using non-recombinant DNA technology. These internal nucleic acid standards are generally chemically synthesized and have a minimum size of approximately 90 nucleic acid bases. Also provided are internal nucleic acid standards prepared using non-recombinant DNA techniques that are single stranded nucleic acids.

WO 01/46463 A2

DT09 Rec'd PCT/PTO 25 JUN 2004

**METHODS FOR THE PREPARATION AND USE OF INTERNAL STANDARDS FOR  
NUCLEIC ACID AMPLIFICATION ASSAYS****FIELD OF THE INVENTION**

5 The present invention relates to a process for the detection and quantification  
of nucleic acids in a sample by using internal nucleic acid standards. Specifically, the  
present invention provides internal controls for nucleic acid amplification assays that  
are derived by chemical synthesis not through recombinant DNA technology  
techniques. More specifically, the present invention relates to chemically synthesized  
single stranded nucleic acid constructs useful as internal controls for nucleic acid  
10 amplification assays.

**BACKGROUND OF THE INVENTION**

The routine determination of nucleic acids in biological samples is of ever-  
increasing importance both in research and in the applied pharmaceutical and medical  
industry. It is of particular importance that biological samples intended for *in vivo* use  
15 be screened for nucleic acids associated with transmissible infectious agents. Many of  
these infectious agents are either uncultivable, or extremely difficult to culture.  
Moreover, immunoassay based detection techniques often lack the sensitivity require  
to detect transmissible infectious agents at extremely low concentrations. Therefore,  
nucleic acid amplification assays have become the detection method of choice.

20 Recently, the number of biotechnology derived therapeutics have increased  
significantly. Biotechnology derived therapeutics include, but are not limited to  
recombinant growth factors, recombinant blood coagulation factors and recombinant  
vaccines. These recombinant materials are produced in *in vitro* cell culture bioreactors  
using recombinant DNA technology. The World health Organization (WHO) and  
25 United States Food and Drug Administration (US FDA) have expressed concern that  
residual heterologous DNA (a DNA construct containing DNA from two or more  
different species) may pose unknown risks. Therefore, these agencies have set limits  
on the amount of heterologous DNA that can be present in a biotechnology derived  
therapeutic. The WHO requires that the quantity of heterologous contaminating DNA  
30 has to be below 100 pg per dose, whereas the US FDA permits a maximum of 10 pg  
of DNA per dose. Consequently, all biotechnology-derived products must be tested  
for residual heterologous DNA content using nucleic acid detection techniques.

Moreover, in addition to the need to screen biological specimens and  
biotechnology derived therapeutics using DNA detection techniques, the burgeoning

10/500050

area of genomic and genetic typing has even further increased the demand for rapid, sensitive and specific nucleic acid detection assays.

Classical methods for nucleic acid detection such as membrane capture hybridization assays (dot blots) have a maximum sensitivity of approximately 5 pg of DNA. However, these assays are tedious to perform and are notoriously difficult to accurately quantify. Moreover, dot blots are generally manual methods that are not suited for large-scale screening. Consequently, the polymerase chain reaction (PCR) assay as described generally in United States patent application numbers (USPAN) 4,683,195 and 4,683,202 is the preferred technique. Since the development of the original PCR technique in the 1980's, many new modification and improvements have been developed. These include, but are not limited to, the reverse transcriptase PCR (RT-PCR), the ligase PCR (LCR) and the Taqman® PCR (referred to hereinafter collectively as either PCR or nucleic acid amplification assays).

Nucleic acid amplification assays possess exceptional sensitivity and specificity. However, all nucleic acid amplification assays are limited in that samples derived from biological fluids such as blood or cell lysates often contain impurities that inhibit the amplification reaction and lead to false negative results. In addition, false negative results arise as a result of nucleic acid loss in the extraction process. Moreover, technical errors during sample preparation and nucleic acid extraction may also contribute to false negative results. Therefore, internal amplification controls may be added prior to the amplification reaction, or prior to the extraction or purification of the nucleic acid, to permit the recognition of false negative results prior to reporting.

Internal controls for PCR assays generally consisting of nucleic acid molecules that contain a detectable nucleic acid sequence (standard oligonucleotide) that is different from the nucleic acid the assay is designed to detect (target oligonucleotide). The standard oligonucleotide is generally flanked by the same primer sequence used to initiate amplification of the target oligonucleotide. When the PCR assay is performed correctly, the standard oligonucleotide will be detected during post amplification analysis. Samples having standard oligonucleotide and target oligonucleotide detected are true positives, samples having only standard oligonucleotide detected are true negatives, samples having only target oligonucleotide detected are false positives and samples having no detectable amplified standard oligonucleotide are false negatives.

Generally, internal standards are made using recombinant DNA techniques that result in a recombinant DNA molecules having the standard oligonucleotide sequence flanked by primers consisting of duplex-DNA. However, standard oligonucleotide preparation using recombinant DNA techniques is a costly, time-consuming process and requires skilled scientists. Tedious internal standard preparation procedures currently being used represent a considerable factor in terms of assay time and cost.

Therefore, there is a need for developing internal standards for nucleic acid amplification assays that can be performed quickly and inexpensively without sacrificing assay specificity or sensitivity.

#### SUMMARY OF THE INVENTION

The present invention provides novel methods for the preparation of nucleic acid amplification assays that address the aforementioned and other problems associated with presently available techniques. In one embodiment of the present invention a process for the detection and quantification of nucleic acids in a sample is provided that consists of adding a chemically synthesized oligonucleotide with a size of at least 90 bases (pairs) to a sample as an internal standard. The sample is then amplified using methods known to those skilled in the art including, but not limited to PCR.

The desired sequence of the internal standard in accordance with the invention is hereby made available in a simple manner by means of chemical synthesis. Numerous firms already exist that offer the synthesis of such oligonucleotides within an extremely short time and at very efficient costs. Oligonucleotide synthesizers such as the Synthesizer 2000 MWG-Biotech AG, Ebenberg (Germany) are also readily available. The quantification of the oligonucleotides synthesized usually takes place automatically in the synthesizer or it is already provided by the synthesizer system. In addition, this quantification is not interfered by the presence of proteins which can be eliminated only as a result of time-consuming, expensive purification and extraction processes in the case of the recombinant DNA techniques in the prior art.

Surprisingly, the process in accordance with the invention is superbly well suited to large-scale industrial use and to comprehensive medical screening tests as a result of the provision of chemically synthesized oligonucleotides with a length of at least 90 bases pairs (bp) as standards, and it specifically offers advantages relative to biologically prepared samples in the organizational and preparative area.

Neither the occurrence of problems with nonspecific bands nor impediments as a result of the formation of primer-dimers have been found in the case of using chemically synthesized oligonucleotide standards starting from a length of approximately 90 bp. In accordance with the invention, use is preferably made, in particular, of standards of a length of 100 to 400 bp and especially 105 to 200 bp.

The term nucleic acid amplification is to be understood primarily to signify processes that are based on the technology that has been developed by Mullis et al. US PAN 4,683,195 and 4,683,202 such as, but not limited to, polymerase chain reaction (PCR), the reverse transcriptase PCR (RT-PCR) or the ligase PCR (LCR).

The standard nucleic acid should advantageously differ from the nucleic acid that is to be amplified in at least one detectable characteristic. In addition, it should advantageously be capable of amplification with the help of the same primer with which the target nucleic acid is amplified. Standard nucleic acids have proven to be practical when they have a different size (e.g., a different number of bases (b) or base pairs (bp) compared to the nucleic acid that is to be quantified or detected). In addition, the use of an additional restriction cleavage site has proven to be advantageous. Otherwise, it is preferable to make use, as the standard nucleic acid, of a nucleic acid that has the greatest possible similarity to the nucleic acid that is to be quantified or detected in the sample. This applies, in particular, to the GC content, the restriction sites, the sequence, etc. Preferred standards differ from the nucleic acid which is to be detected/quantified by at least 10% or 5 bases (base pairs) in terms of their length; in each case, however, these differences also depend on the quantification system for the amplified nucleic acids (for example, gel electrophoresis or a chromatographic process).

The detection and quantification of the amplified nucleic acids can then be undertaken in ways known to those of ordinary skill in the art such as a fluorescence sensitive nucleic acid detection apparatus (if use is made of fluorescent primers). Examples of such nucleic acid detection apparatus are automatic DNA sequencers with laser-induced fluorescence measurement devices, such as the Gene Scanner® 373A from the company Applied Biosystems, or HPLC devices. In the case of these types of apparatus, it is even possible to separate nucleic acid molecules from one another when these molecules differ by only one base pair in terms of their length. Such types of apparatus also permit the processing and analysis of a multitude of samples on a gel (e.g., by means of multiplex PCR).

The internal standard is preferably added to the sample prior to any possible pre-purification or extraction of the nucleic acid from the sample; as a result, false negative results that can arise from errors or losses from such pre-purification can be detected. Routine testing with use being made of 2 or more different internal standards (as described in Austrian patent specification number 401,062), which can also be used at different concentrations, can also be established simply and, in particular, inexpensively via the system in accordance with the invention.

Viral nucleic acids are, preferably, detected or quantified in accordance with the invention, especially those in samples that have been taken from body fluids or that serve as the starting product for medical preparations that are to be administered to humans. Typical clinical samples that are frequently tested using nucleic acid amplification assays include, but are not limited to blood, spinal fluid, semen, saliva and tears. Other samples may include, but are not limited to cell culture fluids, recombinant cells, and animal tissue and plant tissue.

The methodology in accordance with the invention has proven valuable especially in the case of viral nucleic acids that can otherwise be made available only via recombinant manipulation and cultivation of the standard. Preferred viruses which can be detected or quantified in accordance with the techniques of this invention are Transfusion-Transmitted Virus (TTV), human parvoviruses, especially parvovirus B19, hepatitis viruses, especially HAV, HBV and HCV, or retroviruses such as the human immunodeficiency virus (HIV).

Parvovirus B19 causes a disease in children, which usually proceeds in a mild fashion, namely infectious erythema. In immunocompromised persons, however, it can lead to erythema infectiosum and transient aplastic crisis in patients with hemolytic anemia, fetal death, arthritis and chronic anemia (Anderson: J. Infect. Dis. 161 (1990), pages 603-608). Transfusion-Transmitted Virus is a new DNA virus which was isolated recently in the serum of patients with post-transfusion hepatitis of unknown etiology (Simmonds et al.: Lancet 352 (1998), pages 191-194; Okamoto et al.: Hepatol. Res. 10 (1998), pages 1-16).

The present process is also particularly well suited to the characterization of nucleic acids or nucleic acid contamination from culture fluids, especially in a process such as that which is described in Austrian patent number 401,270 B.

The sample which is to be examined in accordance with the invention in this connection is advantageously derived from recombinant cells, tissue or animals,

whereby the detection of contamination or genotyping represents prime usage areas in particular.

The invention will be elucidated in more detail by means of the following examples as well as by the figures, though it is not to be limited thereto.

## 5 BRIEF DESCRIPTION OF THE DRAWING

Fig. 1: Single-stage internally controlled PCR (IC-PCR) for detection of Parvovirus B19. A sample containing Parvovirus B19 DNA was extracted, diluted in tenfold steps: 1 and 3.3  $\mu$ L of the last two dilutions subjected to IC-PCR using primer pair KK5 SEQ ID NO: 1/KK6 SEQ ID NO: 2 (lanes 2-5). Additionally the same dilutions were mixed with approximately 10 copies internal control B19c SEQ ID NO: 8 and PCR amplified (lanes 6-9). 142 bp: fragment of wild-type Parvovirus B19, 117 bp: fragment of internal control B19c SEQ ID NO: 8. Lane 1: negative control: lane 10: molecular weight marker (*Msp*I digest of pBR322).

Fig. 2: IC-PCR for detection of TTV after co-extraction of samples and internal control. DNA was extracted from 200  $\mu$ L plasma of 5 different pools of 32 healthy donors in the presence of approximately 50 copies internal control TTVc SEQ ID NO: 9. 15  $\mu$ L of the extracted DNA solution was subjected to PCR using primer pair TTVS1 SEQ ID NO: 3/TTVA1 SEQ ID NO: 4. The PCR product of the internal control at 105 bp (lanes 1 and 3-5) indicated a successful PCR, a missing PCR product (lane 2) an inhibition of the PCR reaction. A PCR product of 286 bp shows a TTV positive sample (lane 1); lane 6: negative control, lane 7: molecular weight marker (*Msp*I digest of pBR322).

Fig. 3: IC-PCR for genotyping of knockout mice. Tail snips were digested and 3  $\mu$ L of the crude lysate were subjected to PCR alone or separately with both primer pairs in the presence of approximately 10 copies internal control FVIIIc SEQ ID NO:10. Primers MC18 SEQ ID NO: 5/MC19 SEQ ID NO: 6: lanes 1-6, primers MC18 SEQ ID NO: 5/neoR2 SEQ ID NO: 7: lanes 7-12. PCRs in lanes 2, 4, 8, 10 are performed without and in lanes 3, 5, 7, 9 in the presence of the internal control FVIIIc SEQ ID NO:10. A PCR product of 680 bp is from normal mice, 160 bp from knockout mice, the internal control FVIIIc SEQ ID NO: 10 yielded either 105 bp (MC18/MC19) or 85 bp (MC18/neoR2). Lanes 1-7: respective negative controls, lane 13: molecular weight marker (*Msp*I digest of pBR322).

## DETAILED DESCRIPTION OF THE INVENTION

The terms "internal control," "internal standard," "standards nucleic acid" and "standard oligonucleotide" are used interchangeably. All of the aforementioned terms are meant to refer to the novel, chemically synthesized nucleic acid internal nucleic acid amplification assay control of the present invention.

5 Examples:

Example 1: IC-PCR for detection and quantitation of Parvovirus B19 and TTV and genotyping of FVIII knockout mice

The internal controls (designated by a lower case "c" following the target identifier, for example, if the target is HIV, HIVc would designate the internal control nucleic acid) are custom synthesized oligonucleotides of a size of 105 nucleotides for TTVc SEQ ID NO: 9 and FVIIIc SEQ ID NO: 10 and 117 nucleotides for B19c SEQ ID NO: 8 (MWG-BIOTECH GmbH, Ebersberg, Germany) containing the respective forward primer sequences and the complementary sequences of the respective reverse primer. The DNA sequence between the primer sequences was randomly chosen (sequences see Table 1).

Extraction of DNA

Parvovirus B19 DNA was extracted from a sample containing B19 virus with the QIAGEN Blood kit (QIAGEN, Hilden, Germany) following the instructions of the supplier and the DNA was finally eluted with 50  $\mu$ L H<sub>2</sub>O. The indicated amounts of DNA were then subjected to PCR. For TTV, DNA was extracted from 200  $\mu$ L citrated plasma of pools of 32 donors from an anonymous cohort of healthy subjects with the same procedure. In addition, prior the extraction, approximately 50 copies of the single-stranded internal control TTVc SEQ ID NO: 9 were added to the plasma pools. Finally 15  $\mu$ L aliquots were subjected to PCR.

25 Crude lysates of mouse tail-snips

Pieces of tails approximately 5 mm in length were digested for 5 hours at 55°C in 600  $\mu$ L lysis buffer containing 10 mM Tris-HCl, pH 8.3, 2mM MgCl<sub>2</sub>, 0.01% Nonidet®P-40 and 200  $\mu$ g/mL Proteinase K (Roche, Mannheim, Germany). The enzyme was inactivated for 10 min at 94°C, and 3  $\mu$ L of this lysate was subjected directly to PCR.



### Polymerase chain reaction

One to three  $\mu\text{L}$  of tenfold dilutions of the B19 sample, 15  $\mu\text{L}$  aliquots of the extracted TTV DNA samples or 3  $\mu\text{L}$  of the tail-snip lysates were subjected to a single-stage IC-PCR employing a thermally activated DNA polymerase. IC-PCR was carried out in a total volume of 50  $\mu\text{L}$  containing 1 Unit HotStarTaq™ (QIAGEN) in the respective buffer supplied by the manufacturer, 200  $\mu\text{M}$  of each dNTP and 50 pmol each of primers of the respective primer pairs (SEQ ID NO: 1 and SEQ ID NO: 2 for B19 and SEQ ID NO 3 :SEQ ID NO: 4 for TTV. Internal controls were added to TTV samples already to the extraction procedure, to the B19 samples and to the tail lysates they were added to the indicated reaction tubes prior to PCR. The sequences of all primers and of the internal controls are shown in Table 1. Samples were then overlaid with mineral oil, incubated for 14 min at 94°C and amplified for 45 cycles in a TRIO-Thermoblock (BioMetra, Göttingen, Germany) with the following cycle profile: 30 s at 94°C, 30 s at 55°C, 60 s at 72°C with a final elongation of 72°C for 1 min. The samples were fractionated on a 3.5% low-melting agarose gel stained with ethidium bromide.

### RESULTS

It was previously reported that the use of a Taq DNA polymerase inactive at room temperature has a comparable sensitivity and specificity as nested PCR (Zimmermann et al. BioTechniques 24 (1998), page 222-224) which usually detects single copies of specific templates. In order to achieve highest sensitivity and specificity in a single-stage PCR protocol, a thermally activated DNA polymerase is used. To check the sensitivity of the single-stage PCR set-ups, calculated concentrations of the internal controls were endpoint diluted and repeatedly PCR amplified.

The principle of a single-stranded custom synthesized internal control was first checked in a PCR set-up for the detection of single-stranded DNA virus Parvovirus B19. DNA from a sample containing the virus was extracted and then diluted in tenfold steps to an endpoint. Then 1 and 3.3  $\mu\text{L}$  of the last two dilutions were subjected to PCR. The same concentrations of the B19 sample were also mixed with approximately 10 copies internal control B19c SEQ ID NO: 8. This was the lowest amount necessary always leading to PCR amplification products. The samples were PCR amplified with primers KK5 SEQ ID NO: 1/KK6 SEQ ID NO: 2 located in the highly conserved region of B19 from bp 961 to bp 1102 (PVBAOA strain). Fig. 1

shows that the internal control produced a fragment of the expected 117 bp size (lanes 6-9). It should be noted that the lowest concentration of B19 visible without internal control (lane 4) was in this concentration influenced in it's intensity but still clearly visible if mixed with an amount of approximately 10 copies B19c SEQ ID NO: 8 (lane 8). To control extraction efficiency the internal control B19c SEQ ID NO:8 is added prior to a DNA extraction procedure.

The detection of TTV was chosen for demonstrating the usefulness of single-stranded oligonucleotides as internal control for a nucleic acid co-extraction procedure. Because TTV is frequently detected by PCR amplification using various PCR methods and primer sets which are all specific for the same region located in the ORF of TTV (Naoumov et al. Lancet 352 (1998), page 195-197; Nishizawa et al. BBRC 241 (1997), page 92-97; Okamoto et al.; Simmonds et al.). A primer set specific for this region (TTVS1 SEQ ID NO:4/TTVA1 SEQ ID NO: 4) is chosen. Due to a recovery of less than 100% during DNA extraction approximately 50 copies of internal control TTVc SEQ ID NO:9 was the smallest possible number to be added prior to the TTV DNA extraction resulting in positive PCR amplification products. The internal control was added to 200  $\mu$ L plasma consisting of pools of 32 donors, the samples were extracted and then subjected to IC-PCR. An example for typical IC-PCR experiments is shown in Fig. 2 where a TTV positive sample is shown in lane 1 and a missing PCR product of the internal control at lane 2 indicates an inhibition of the PCR. The PCR product of the internal control at 105 bp (lanes 1 and 3-5) indicates a successful PCR.

The examples of Parvovirus B19 and TTV demonstrate that single-stranded oligonucleotides are useful tools for IC-PCR, but it is still unclear if they could be used equally well in PCR set-ups analyzing double-stranded DNA. This PCR is also used for analysis of FVIII knockout mice as an example to check the tissue. The E-17 factor VIII-deficient mouse strain was produced by Bi et al. (Nat. Genet. 10 (1995), page 119-121; Blood 88 (1996), page 3446-3450) by insertion of a neomycin gene into the 3' end of exon 17 of the factor VIII gene. One of the strategies for breeding is the crossbreeding of normal C57BL/6 females with semizygous affected knockout males (Muchitsch et al. Throm.Haem. 82(4) (1999), page 1371-1373).

To determine the zygosity of the offspring, crude lysates of tail snips are routinely genotyped. Especially to ascertain the heterozygosity of X'X females in crude lysates the addition of internal controls prior to PCR proved to be extremely helpful. An oligonucleotide containing the sequence of MC18 SEQ ID NO: 5 at the

5' end and the complimentary sequences of ne2R SEQ ID NO: 7 and MC19 SEQ ID NO: 6 at the 3' end (resulting after PCR in 85 and 105 bp fragments, respectively) was ordered. Thus, this internal control termed FVIIIc SEQ ID NO: 10 could be used both for amplification with either primer pair MC18/neoR2 resulting in a 160 bp fragment from factor VIII gene of knockout mice or for a separate amplification with MC18/MC19 of knockout mice or for a separate amplification with MC18/MC19 yielding a 680 bp fragment from factor VIII gene of normal mice.

Again, for crude lysates the addition of approximately 10 copies FVIIIc SEQ ID NO: 10 prior to PCR were the lowest number necessary always leading to PCR signals. Fig. 3 shows a typical example of a genotyping experiment performed with two chosen samples of X'X females. Both samples were amplified alone or in the presence of the internal controls with either primer pair MC18 SEQ ID NO: 5/MC19 SEQ ID NO: 6 (lanes 1-6) or MC18 SEQ ID NO: 5/neoR2 SEQ ID NO: 7 (lanes 7-12). Sample 1 (lanes 2, 3, 8, 9) showed all expected bands of the specific template and the internal control with both primer pairs whereas sample 2 (lanes 4, 5, 10, 11) containing obviously PCR inhibitors resulted in only faint bands with MC18/neoR2 (lanes 10 and 11) and in no bands with MC18/MC19 (lanes 4 and 5). Only the use of an internal control avoided a false determination of the genotype.

Example 2: Serial testing of TTV according to the present invention with a comparative test to nested PCR and semi-nested PCR

## METHODS

### Extraction of DNA

Citrated plasma samples were collected from an anonymous cohort of healthy plasma donors. All were HBV, HCV and HIV-1 negative regular donors. DNA was extracted from 200 µL plasma of a pool of 32 donors with the QIAGEN Blood kit (QIAGEN, Hilden, Germany) following the instructions of the supplier. In addition, prior to the extraction procedure, approximately 50 copies of the single-stranded internal control TTVc SEQ ID NO:9 were added to the plasma pools and the DNA was finally eluted with 50 µL H<sub>2</sub>O. The internal control is custom synthesized 105 base oligonucleotide (MWG-BIOTECH GmbH, Ebersberg, Germany) containing the primer sequence of TTVS1 SEQ ID NO: 3 and the complementary sequence of TTVA1 SEQ ID NO: 4.

### Polymerase chain reaction

The extracted DNA solution of the plasma pools was divided in 15  $\mu$ L aliquots and subjected either to nested PCR as described by Simmonds et al., to semi-nested PCR as described by Okamoto et al., (Taq DNA polymerase and 10x buffer from  
5 Pharmacia, Uppsala, Sweden), or to single-stage IC-PCR employing a thermally activated DNA polymerase. IC-PCR was carried out in a total volume of 50  $\mu$ L containing 1 Unit of HotStarTaq™ (QIAGEN) in the respective buffer supplied by the manufacturer, 200  $\mu$ M of each dNTP and 50 pmol each of forward primer TTVS1  
10 SEQ ID NO: 3 and reverse primer TTVA1 SEQ ID NO:4. The sequence of all primers and of the internal controls are shown in Table 1. Samples were overlaid with mineral oil, incubated for 14 min at 94°C and amplified for 45 cycles in a TRIO-Thermoblock (BioMetra, Göttingen, Germany) with the following cycle profile: 30 s at 94°C, 30 s at 55°C, 60 s at 72°C with a final elongation at 72°C for 1 min. The  
15 samples were then fractionated on a 3.5% low-melting agarose gel stained with ethidium bromide. Amplification of a positive sample with primer pairs TTVS1 SEQ ID NO:3-TTVA1 SEQ ID NO: 4 resulted in the expected 286 bp PCR product and of the internal control in a 105 bp band.

### RESULTS

In order to achieve the highest sensitivity and specificity in a single-stage PCR  
20 protocol, HotStarTaq™ was used. To determine the sensitivity of this single-stage PCR set-up, the internal control, a simple, custom synthesized 105 base oligonucleotide, was endpoint diluted and repeatedly PCR amplified. Taking into account the Poisson distribution, the sensitivity of our assay was confirmed to be on the single copy level. The IC-PCR is compared with the nested and semi-nested PCR  
25 protocols most frequently used at the time for amplification of the same TTV region (Charlton et al. Hepatology 28 (1998), page 839-842; Höhne et al. J. Gen. Virol. 79 (1998), page 2761-2764; Naoumov et al., Nishizawa et al., Okamoto et al., Prescott et al. NEJM 339 (1998), page 776-777; Simmonds et al., Tanaka et al. J. Med. Virol. 56 (1998), page 234-238 and FEBS Letters 437 (1998), 201-206). Considering the  
30 previous data (Simmonds et al.), a low prevalence in a European population for this region of TTV was expected and therefore compared 20 different pools consisting of the plasma of 32 donors to obtain more positive samples.

Approximately 50 copies of the internal control (the lowest number necessary always leading to PCR signals) were added to 200  $\mu$ L plasma, the sample was

extracted and then subjected to IC-PCR, to the nested PCR as described by Simmonds et al. and to the semi-nested PCR as described by Okamoto et al. All samples were independently extracted and subjected to the different PCRs (including positive and negative control) three times. The results are summarized in Table 3. The  
5 comparison of the three methods shows a comparable sensitivity and specificity of our method and the method of Simmonds (13/20 vs 11/20 samples positive), whereas in our hands, the PCR set-up as described by Okamoto et al. did not work. From 60 IC-PCRs two reactions were inhibited once (samples 1 and 18) and the two other tests were positive. In contrast to IC-PCR, in these two cases, the conventional PCR would  
10 have given false-negative results. Samples 3, 4 and 12 always showed the band of the internal control, but were only positive in two of three PCR experiments, which is probably due to the low copy number of TTV often present in plasma (PCR methods for TTV are obviously at the border of delectability).

Table 1: Sequences of primers and internal controls

Target	Sequence	Oligotype	Primer Sequence	Length of fragment
Parvo B19	KK5	Forward	SEQ ID NO: 1 5'-CCAAGAAACCCCGCATTACC-3'	142 bp
	KK6	Reverse	SEQ ID NO: 2 5'-ACCAGTTTACCATAGTTTGAA-3'	
TTV	TTVS1	Forward	SEQ ID NO 3 5'-ACAGACAGAGGAGAAGGCAAC-3'	286 bp
	TTVA1	Reverse	SEQ ID NO: 4 5'-CTGGCATTTTACCATTTCCAA-3'	
FVIII knockout	MC-18	Forward	SEQ ID NO: 5 5'-GAGCAAATTCCTGTACTGAC-3'	approx. 680 bp
	MC-19	Reverse	SEQ ID NO: 6 5'-TGCAAGGCCTGGGCTTATTT-3'	(MC18/MC19)
	neoR2	Reverse	SEQ ID NO: 7 5'-CCGCCCTCCCTTGCGCTAC-3'	approx. 160 bp (MC18/neoR2)
Parvo 19	B19c	Internal Control	SEQ ID NO 8: 5'-GCCAAGAAACCCCGCATTAC CATGTTATGGATAGACTGGC TAAGCAAAGCGCGATCCAAA ACACAAAAGGCTTTGTTCTT TACTCTTTAACTTTGTTCA AACTATGGTAAACTGGT-3'	117 bp
TTV	TTVc	Internal Control	SEQ ID NO: 9 5'-ACAGACAGAGGAGAAGGCAA CATGTTATGGATAGACTGGC TAAGCAAAAAACACAAAAG GCTTTGTTCTTACTCTTTA AACTTTGGAAATGGTAAAAT GCCAG-3'	105 bp
FVIII knockout	FVIIIc	Internal Control	SEQ ID NO: 10 5'-GAGCAAATTCCTGTACTGAC CATGTTATGGATAGACTGGC TAAGCAAAGCGCGATCCAAA	105 bp (MC18/MC19)

ACACAAGTAGCGCAAGGGAG  
GGCGGAAATAAGCCCAGGCC  
TTGCA-3'

85 bp  
(MC18/ne  
oR2)

Table 2: Sequences of primers and internal control

NG059	SEQ ID NO: 11 5'- ACAGACAGAGGAGAAGGCAACATG-3'
NG061	SEQ ID NO: 12 5'- GGCAACATGTTATGGATAGACTGG-3'
NG063	SEQ ID NO: 13 5'- CTGGCATT TTTACCATTTCCTAAAGTT-3'
A5430	SEQ ID NO: 14 5'- CAGACAGAGGAGAAGGCAACATG-3'
A5427	SEQ ID NO: 15 5'- TACCAYTTAGCTCTCATTCTWA-3'
A8761	SEQ ID NO: 16 5'- GGMAAYATGYTRTGGATAGACTGG-3'
A5432	SEQ ID NO: 17 5'- CTACCTCCTGGCATT TTTACCA-3'

Table 3: Comparison of three different PCR methods for the detection of TTV

Sample No.	IC-PCR	Nested	Semi-nested
	1 2 3	1 2 3	1 2 3
1	+ + i	+ + -	- - -
2	+ + +	+ + +	- - +
3	+ - +	- - -	- - -
4	- + +	- - -	- - -
5	+ + +	+ + +	- - -
6	+ + +	+ + -	- - -
7	+ + +	+ + +	+ + +
8	- - -	- - -	- - -
9	- - -	- - -	- - -
10	+ + +	+ + +	- + -
11	- i -	- - -	- - -
12	- + +	- + -	- - -
13	+ + +	+ + +	- - -
14	- - -	- - -	- - -
15	- - -	- - -	- - -
16	+ + +	+ + +	- - -
17	- - -	- - -	- - -
18	i ++	- + +	- - -
19	+ + +	+ + +	- - -
20	- - -	- - -	- - -

Each sample (pools of 32 donors) was extracted three times and each extracted solution subjected to the three different PCR set-ups: + = positive, - = negative, i = inhibition of reaction

Reference has been made herein to various patents, printed publications and manufacture instructions for use. Each of the aforementioned references is

5 incorporated herein by reference in their entirety.



What is claimed is:

1. An internal control for a nucleic acid amplification assay comprising:  
5 a synthetic nucleic acid wherein said internal control is made using non-recombinant DNA techniques.
2. The internal control of claim 1 wherein said non-recombinant DNA technique is chemical synthesis.
- 10 3. The internal control of claim 1 herein said non-recombinant DNA technique uses a oligonucleotide synthesizer.
4. The internal control of claim 1 wherein said synthetic nucleic acid is single stranded DNA.
5. The internal control of claim 1 wherein said synthetic nucleic acid is single  
15 stranded RNA.
6. A method for the detection of nucleic acids in a sample, comprising:  
providing a sample;  
adding at least one internal nucleic acid standard to the sample;  
amplifying nucleic acids present in said sample; and  
20 detecting said amplified nucleic acids;  
wherein said at least one internal standard is an oligonucleotide synthesized using non-recombinant DNA techniques.
7. The method for the detection of nucleic acids in a sample of claim 6 wherein said method is a quantitative polymerase chain reaction (PCR) assay.
- 25 8. The method for the detection of nucleic acids in a sample of claim 6 wherein said internal nucleic acid standard differs from a target nucleic acid to be detected and wherein said internal standard and said target nucleic acid have at least one detectable difference.

9. The method for the detection of nucleic acids in a sample of claim 6 wherein said nucleic acids are extracted prior to amplifying said nucleic acids in said sample, and whereby said internal nucleic acid standard is added prior to said extraction of said nucleic acids in said sample.
- 5 10. The method for the detection of nucleic acids in a sample of claim 8 wherein said target nucleic acid is viral nucleic acid.
11. The method for the detection of nucleic acids in a sample of claim 10 wherein said viral nucleic acid is selected from the group consisting of transfusion transmissible virus nucleic acid, parvoviruses nucleic acid, hepatitis B virus nucleic acid, hepatitis C virus nucleic acid, and human immunodeficiency virus nucleic acid.
- 10 12. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is selected from the group consisting of blood, spinal fluid, semen, saliva and tears.
13. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is cell culture fluid.
- 15 14. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is selected from the group consisting of recombinant cells, animal tissue and plant tissue.
15. The method for the detection of nucleic acids in a sample of claim 8 wherein said internal nucleic acid standard differs from said target nucleic acid in terms of its length.
- 20 16. The method for the detection of nucleic acids in a sample of claim 15 wherein said internal nucleic acid standard differs from said nucleic acid by at least 10% or 5 bases (base pairs) in terms of its length.

FIG. 1




FIG. 2




FIG. 3



## SEQUENCE LISTING

10/500050

<110> BAXTER AG  
Turecek, Peter  
Zimmermann, Klaus  
Schwarz, Hans-Peter

<120>

<130>

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 1

gccaaagaaac cccgcattac c

21

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 2

accagttttac catagttttga a

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 3

acagacagag gagaaggcaa c

21

<210> 4

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 4

ctggcatttt accatttcca a

21

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 5

gagcaaattc ctgtactgac

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 6

tgcaaggcct gggcttattt

20

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 7

ccgccctccc ttgcgctac

19

<210> 8

<211> 14461

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 8

```

arcssrthdt ctnandantc atnnccacds nasamthnvn tnrtanstar cssrthdtct 60
nandantcat nccacdsna sambysngnt rnanccacds tandardsth rtndtrmnat 120
nccacdsnb gcasamssvr ncrasngmrt ancbthnrsa rchandntha dharmactca 180
andmdcands trynthscnn ctnndamnta mrtancsatt achdnartca rtthdtctnc 240
ntamnatngn ccacdsnmde ascrnngtst swthaargnm brndvdasam sthatartba 300
mndnthcast hatychckng btchngcayb tandrtnsmr vrtsasncss arytdtctmr 360
tsthatadrdr vdrmtthctr nstnrcmanc wthcrtandn abmtsrscrm rtsthsthr 420
dhathrgana tnramrrsth atthanttyh trgsentamn atngdnahas tbbwgrdsad 480
mnstrdnrcm bnantrdets thdtrmnatn sthsdanddr gadmnstrat narstmrstr 540
ngnthratth vrymstcnta mnatnbygdn arndvdadss acctdanadd tnaargaras 600
rthdtctnan dantcatnnc cacdssrrsn tdbythgnty ngvarsndvd asgcsranma 660
srdcdbyrcm bnanttchns andasbymdc ascrnngtst snrgardtnc cacymrhsm 720
dnacanbdtc tddwntgvat hcasscamth dgyrthdtrm natncntamn atngdnanam 780
ybyhybrdat nmmbransw hnradactvy abdgnmcrbs arsdwhrthm thdsntrgar 840
ddasbngvry rabscaynrg ardtanttat vnrmatnhwv rthasbnssb tmakmthdsa 900
vaabvathst abshmntncc acdamcatnr cssswhrbyt hsmthdsrmt thcntantca 960
tnanddtctn nccacdnths samsbymans nccacdama tncncasams thathavbnd 1020
rvdrmbgcad sschasbdrc ysatstncnt anmrtsthat nhbtthamca tnactnand 1080
adtasngatv rstnschts tsystmsnad dtnntrrncc anarsdrnga mcatnasars 1140
tthssnccac dsnthtract nrcssmrvt chncarrsr rrrsdrngsa mraratnrth 1200
nccacdact narasssbth sthsntrnac ntrswchar adddrtrtha mcatnractn 1260

```

```

rrrtthtrac  tnrrcatnth  nccacdhavr  vntbadvant  agsrrvntng  asngatvrst  1320
snthscnnct  nthrcsssth  atardscrbd  natsandnwh  chnccacdan  tcatnwasca  1380
rrdtvathad  dtnntrnast  andardsart  bmhasdnart  carnaccrda  ncwththnvn  1440
tnsthatard  scrbdthras  asnthrmann  grrartnwhc  hnccacddtc  tnandantca  1500
tnrcssshav  bncarrdtwt  hsntrnasta  ndardsthst  andardsara  waysrardva  1560
abgcartsay  wththhasmd  cnstrectshw  vrschntrna  standardsa  rstsdtratvy  1620
rarynrtrnc  ssswhrbyth  ssrbabycas  dnartcarby  thtmcnsmng  rcssrthrra  1680
ratnschbge  arcsssrthr  aratnstand  ardncacds  argnraynsv  sncthycmrs  1740
thcnstrectn  gntccnstrc  tsschasgas  mdsthramca  tnramvacnn  gandthctva  1800
tnrgansmst  hatcntanth  scnstrctsa  ndthrcatnt  hcrrsndngs  tandardncc  1860
acdaccrata  ntcantandc  hckngthrar  atnthssstan  dardnccacd  srrdsbsnty  1920
aswthsstsh  avtbcarrdt  anwandndnd  ntyrachndv  dastandard  thstdsrara  1980
tnthstanda  rdsrrsntsa  cnsdrabact  rntrmstman  dcstscayrs  crngtstst  2040
hatartbcar  rdtrtnysca  ywhnthstan  dardshavtb  sctdnaryyb  mannrschas  2100
ramnthcasc  ntamnatnch  cksrgntyng  thrsntnvnt  nthrrststs  thrbmakng  2160
avaabanmrv  drcssrthdt  ctnandantc  atnncacds  nasamwthsb  ngmadntrna  2220
standardsw  hrbyschrcs  sscanbcarr  dtnamannrt  hatsmravra  bntrmcssta  2280
ndthatsmrc  ntandastrt  hrbmnaccrd  ancwththnv  ntnssvdbya  rcssrthdtc  2340
tnandantca  tnccacdsn  asamcmrsng  thststhvrs  nasamthadd  tnatastnt  2400
rnancacds  tandardtth  samcarryng  tanamcatnr  actnnwhcht  hstandarda  2460
ndrrdatast  nthnccacds  whchstbant  dnthsamars  mtansyamda  ndthdtctna  2520
ndantcatnt  hamdnccacd  swchschsar  actrdnthat  achmcaysyn  thsdgnctdw  2580
thasatastb  assarssadd  dtthsamasa  nntrnastan  dardthdsrd  sncthntrna  2640
standardna  ccdancwth  thnvntnshr  bymadavaab  nasmmannrb  ymanschmca  2700
synthssnmr  srmsaradys  tthatrthsy  nthssschgn  ctdswthnan  trmyshrttm  2760
andatvrycn  tcstasars  cadgnctdsy  nthsrsscha  sramgsynth  ssrmwgbtch  2820
agbnbrggrm  anythantca  tnthgnctds  synthdsay  taksacatma  tcaynthsyn  2880
thsrrtsara  dyrvddbyth  synthsrsys  tmnaddtnth  santcatnsn  tntrrdbyth  2940
rsncrtnswh  chcanbmnat  dnyasarstt  mcnsmgnsv  rcatnandtr  actnrcsssn  3000
thcasthbg  craratnsta  ndardsnthr  rartsrrsng  ythrcssnac  crdancwtht  3060
hnvntnssrb  ywstdtargs  candstrasa  ndtcmrhnsv  mdcascrnng  tstsasarst  3120
thrvsnchmc  aysynthsdg  nctdswthan  gthatastba  ssarsassta  ndardsandt  3180
sccayrsadv  antagsratv  tbgcayrard  samsnthrga  natnaandra  ratvaranth  3240
rthccrrncr  bmswthnnc  cbandsnrmd  mntsasarst  thrmatnrmr  dmrshavbnn  3300
dnthcassng  chmcaysynt  hsdgnctdst  andardssta  rtngmangt  harmatybna  3360
ccrdancwth  thnvntnssr  rabymadnar  tcarstanda  rdsangthtb  andscaytbt  3420
htrmnccacd  amcatnstbn  drstdrmayr  tsngnyrcss  thatarbasd  nthtchngyt  3480
hathasbndv  dbyvnmstas  sandgthymr  aschanract  ncrthrvrst  ranscrtasc  3540
rrtcrrthga  scrctthsta  ndardnccac  dshdadvant  agsydrmmth  nccacdwhch  3600
stbamdnata  stndtctabc  haractrstc  naddtnntshd  advantagsy  bcaabamcat  3660
nwththhths  amrmrwthwh  chthtargtn  ccacdsamd  thcntamnan  tthatstbdt  3720
ctdstandar  dnccacdsha  vrvntbract  cawhntyha  vadrntsgad  rntnmbrbas  3780
sbrbasarsb  cmardtthnc  cacdthatst  bantdrdtct  dnaddtnths  anaddtnars  3840
trctncavag  sthasrvntb  advantagst  hrwstsrab  tmaksasths  tandardncc  3900
acdancacd  thathasthg  ratstssbsm  artytthncc  acdthatstb  antdrdtctd  3960
nthsamthsa  snartcartt  hgcentntth  rstrctnsts  thsncterrr  dstandards  4020
drmmthncca  cdwhchstbd  tctdantdb  atastrbass  basarsntrm  sthrngthna  4080
chcashwvrt  hsdrcnsasd  ndnthantca  tnsystmrth  amdncacds  ramgctrhrs  4140

```

srachrmatg rahcressth dtctnandan tcatnthamd nccacdsan thnbndrtak 4200  
 nnawaythat skwnnassch whrbythdtr mnatnrraby taksacwths bngmadancc 4260  
 acddtctnaa ratsgarscn csnstvncca cddtctnaar atsssmadrs cntrmrsams 4320  
 schncacdd tctnaarats aratmatcdn asncrswtha srndcdrcsn cmasmntdv 4380  
 csschasgth gnsannrra rmthcmanya dbsystmsrh cdvcsnthca sthstysaar 4440  
 atstsvnssb tsaratncca cdmcscrman thrwhnthsm csdrbynynb asarntmst 4500  
 hrngthscht ysaaratsas rmtthrcssn gandamayss amtdsamsn aggbymansm 4560  
 tcrthntrna standardsr rabyadddt hsamrrtany ssbrrcatnr tractnthnc 4620  
 cacadrmthsa masarstasn gatvrstsw chcanarsrm rrrsrssrm schrrcatnc 4680  
 anbtrdtrtn tstngwthsb ngmadrmrdr nttrnasta ndardsasds crbdnatswh 4740  
 chcanasbsd atrntcn cn tratscana sbstabshds myandnartc arnnsvyvat 4800  
 hsystmnacc rdancwthth nvntnvranc cacsarrra bydtctdran tdnaccrdan 4860  
 cwththnvnt nscaythsns amsthathav bntaknrmdb ydsrthatsr vasthstart 4920  
 ngrdctrmdc araratnsth atartbadmn strdthmans thmthdgyna ccrdancwth 4980  
 thnvntnhas rvnvaabsca ynthcasvra nccacdस्था tcanthrwsb madavaabny 5040  
 varcmbnant manatnandc tvatnthsta ndardrrrdv rsswhchcan bdtctdrant 5100  
 dnaccrdanc wththnvntn arttvtrans sntransmtt dvrsarvvr sscayarvvr 5160  
 sbhattsvrs sscayhavhb vandhcvrrt rvrssschas thhvrarvv rsbcassads 5220  
 asnchdrnwh chsayrcdsn amdashnnam ynctsrhythm anmncmtnt rsnshwvrtc 5280  
 anadtrythm anctsmant ransntaast ccrssnatnt swthhmytca nmatadatha 5340  
 rthrtsandc hrncanmaan drsnncdsa gsttvsanwd navrswchhw assatdrcnt 5400  
 ynthsrmatn tswthsttra nssnahatts nknwntgysm mndstaant agskamtah 5460  
 atrsagsthr sntrcssas artcarywst dtthcharac tratnccac dsrnccacdc 5520  
 ntamnatnrm ctrdsscayn arcssschas thatwhchsd scrbdngatb thsamwhchs 5580  
 tbamndnacc rdancwthth nvntnnthsc ncnctnsadva ntagsydrvd rmrcmbnant 5640  
 cstssranma swrbythdt ctncntamna tnrgntyng rsntrmsag arasnartca 5700  
 rthnvntnwb cdatdnmrtd abymansthw ngamsaswas bythgrsthg htsnttbmtd 5760  
 thrtgngst agccrtrna ycntrdcrd tctnarvbas amcntannga rvbdnawast 5820  
 ractddtdnt ndtsandth asttwdtnss bctdtccrsn grmrarkkkk ansaddtnay 5880  
 thsamdtnsw rmdwtharma tycsntrnac ntrbcandcr amdansbrag mntwdtyarv 5940  
 bbragmntnt rnacntrbca nngatvctr anmcarwght markrmsdgs tbrgccrrdt 6000  
 ctnttvatrc tractnsams andntrnacn trdnawastr actdrmasma drntshathy 6060  
 dnrsnthrsn carmatycsn trnacntrtt vcthractd dnastnwass bctdtersng 6120  
 rmrarttvst tvathcrrdc tthntrnacn tratbansan dndcatdasc csscramssn 6180  
 gcrrdctana nnhbntnhr ractnacrrd ctbshwsatt vstvsamana nngatvctr 6240  
 anmcarwght markrmsdgs tbrgccrrgn tyngkncktm ctasns wrdg stdandthcr 6300  
 dysatwrsbc tdtcranrsa ratywthbth rmrarsnthr snrcarmatyc sntrnacntr 6360  
 vcrmrsmcmc ansrmrsmcn ranscrsnan sarrmrdwth tandnañnt hrsncthntr 6420  
 nacntrvcac rrdctbsrmn rmamcbrmkn cktmcthntr nacntrvcyd dthrbmcmcr 6480  
 bmcnransrs ctvngatvcr trsanmcarw ghtmarkrms dgstbramsa mccrrdtctn 6540  
 andanttatn arvvrband ttvandgnty ngvkncktm mthdsntrna cntrsthnt 6600  
 nacntrsarc stmsynths gnetdsasnc tdsrttvcn dvcandnctd srbcmwgbtc 6660  
 hgmbhbrsbr ggrmanyent annghrset vrwardrms ncsandthcm mntarysncc 6720  
 thrsetvrvr srmrthdnas ncbtwnthrm rsncswasra ndmychsncc csstabtrac 6780  
 tndnaarvbd nawastract drmasamcnt anngbvrswt hthagnbdkt agnhdngrma 6840  
 nywngthnst rctnsthra ndthdnawas naytdwthht hndcatdamn tsdnawrthn 6900  
 sbctdctrrt tvdnawastr actdrmcetra tdasmasdnr srmanannym schrrthathy 6960  
 sbctswthth samrcdrnad dtnrrthtra ctncarmatyc sthsngstra nddntrnacn 7020



trttvcwrad	ddtthasmas	nayatswrsb	ctdtcrerdy	satsmstasn	scstasarma	7080
tymnngthw	rdgstdrhrs	atcnysbrc	ntanngmmtr	shchmmngcn	ndtrandgmr	7140
tnaskrchma	nnhmgrmany	thnymwasna	ctvatdrma	tcandthsys	atwassbctd	7200
drcytycrym	raschanrac	tntnddtnt	hbsamatsth	tractdttvd	nasamsrtht	7260
asnysatswr	sbctdtasng	stagccrmyn	gathrmayac	tvatddnaym	rascrrwasc	7320
arrdtnatta	vmcntanng	tstartatma	gnnthrsctv	brsdbythma	nactrrmach	7380
dntandmach	rmrsthrst	vrmrarsnr	nacntrswra	dddtttvsam	saradyttht	7440
ractnrdrct	thbsamsand	tthtaysats	thywraddt	thndcatdra	ctntbsrrtc	7500
rthsnscsarm	rsandthntr	nacntrsars	hwnntabsam	swrthnvrad	wthmnrancb	7560
atdrmnatca	ndamdrccys	natrthrmbc	kbmtragtn	gngrmanywt	hthwngcyer	7620
satsatcsa	tcwthanang	atncrmnth	amswractn	atdnawmtng	agrgstand	7680
wththdmbrm	drststwasr	vsyrrtdtha	tthsatadna	ymrasnactv	atrmtratr	7740
hasacmarab	snstvtvand	scctyasnst	dcrmmrmann	tabtchnsag	whchsdytc	7800
tssngcsscc	tmatsnrdr	achvhghsts	nstvtvyands	cctynasngs	tagcrrtc	7860
hrmayactva	tddnaymras	ssdtchckth	snstvtvyths	ngstagcrst	scacatdcnc	7920
ntratnsthn	trnacntrsw	rndntdtdan	dratdycram	dnachcastw	ascnrmtdha	7980
tthsnstvt	thassayswr	atastnawcy	vthrnccasng	stranddcst	msynthsdt	8040
rnacntrwas	rstchckdna	crstrthdtc	tnsngstran	dddnavrars	vbdnarmasa	8100
mcntanngth	vrswastrac	tdandthndt	dntndststa	nndntthnan	dthasttwdt	8160
nswrsbctdt	crthsamcnc	ntratnsthb	samwrasmcw	tharmatyces	ntrnacntrb	8220
cthsawsthw	stamntncss	aryawaysad	ngtcramcat	nrdctsthsa	mswrcramdw	8280
thrmrskkkk	catdnthhgh	ycnsrvdrn	brmbtbvbaa	strangshws	thattthntrn	8340
acntrrdeda	ragmntthct	dbsanstshd	bntdthath	wstcncntra	tnbvsvwtht	8400
ntrnacntra	nwasnthscn	cntratnnnc	dntsntnsty	btstcaryvs	bmdwthanam	8460
ntarmatyces	bcantcntrt	ractncncy	hntnacntr	bcsadddr	adnatractn	8520
rcdrthdtct	nttvwaschs	nrdmnstrat	ngthsnsssn	gstranddgn	ctdsasntn	8580
acntrrance	acdctractn	rcdrsncttv	srntydtctd	bycramcatn	sngvarscrm	8640
thdsandrnr	stswwhchara	scctrhsamr	gncatdnthr	ttvnamvtaa	nctagnshaw	8700
atabbrcagk	amttasmnd	staarmrst	ccrthsrnt	tvsttvasch	sndtarcvry	8760
ssthandrng	dnatractna	rmatyecntr	nacntrttvc	wasthsmast	ssbnmbtrba	8820
dddrtrthtt	vdnatractn	rstngnstvc	ramcatnrde	tsthntnac	ntrwasadd	8880
tasmacnsst	ngsdnrsths	amswrtract	dandthnsbc	tdcccranam	rtycaccrm	8940
ntssshwnng	whrattvstv	samsshwnna	nandamssng	crrdctthnt	rnacntrata	9000
nndcatsann	hbtnttherth	crrdctthnt	rnacntratb	ansandndca	tsasccsscr	9060
thamsarvba	ndttvdmnst	ratthatsng	stranddgnc	tdsarstsrc	crbttsstnc	9120
arthycdbsd	aywnrcrsta	nayngdbstr	andddnaths	crsassdran	ayssvknckt	9180
mcasanamtc	hckthtssth	actrvdcntm	sstranwasr	dcdbybtana	tgntagbdag	9240
bynsrtnanm	ycngnntthn	dnthactrv	gnnthstratg	srbrdngsth	crssbrdngn	9300
rmacbmawt	hhmygsactd	kncktmasc	htschtathr	mhamagtdtr	mnthygstyt	9360
hsrngcrdys	atstasnsar	rtnygntyds	caytascrta	nthhtrygst	ymasncrdys	9420
atsthaddtn	ntrnacntrs	rtrcrrvdtb	trmyhangnc	tdcntanngt	hsncmcath	9480
ndandthcm	ntarysnscn	randmcath	ndrstngatr	crnandbrag	mntsrscv	9540
wasrdrdths	thsntrnacn	trtrmdvcc	bsdbthramc	atnwththrr	mrarmcnrrs	9600
tngnabragm	ntrmactrv	kncktmccr	asaratamca	tnwthmcmck	ncktmccrras	9660
aratamcatn	wthmcmcydn	gabragmnr	mactrvgnnr	mamcaganas	rcrdysatst	9720
haddtnarma	tycsvcrctc	rwtrhwstnm	brncssarya	waysadngtc	rsgnasgshw	9780
satycaamag	ntyngmnr	rmdwthtwch	snsamsmasb	thsamswram	danrnthrsn	9840
cthntrnacn	trswththrr	mrarmcmcan	srmcnranss	amansshwda	ctdbandsth	9900

sctmatand thntrnacnt rwthbthrmr arswhrassa manscntann gbvsycrnhb 9960  
 trsrstdnny antbandswt hmcnransan dandnnband swthmcmcan sandnythsa 10020  
 nntnacntr avddaasdtr mnatnthgnt yamsratstn gttvaccrdn gtthrsntnv 10080  
 ntnwthacma ratvtsttns tdcrandhmn stdcrmthds tractndnac tratdasma 10140  
 amswrcctdr manannymsc hrthathyas madnrsawrh bvhcvandhv ngatvrgard 10200  
 nrdsnawast ractdrmasm aadnrswtht hagnbdktag nhdngrmany wngthnstrc 10260  
 tnstharnad dtnrrtthtr actnrdrar matycsthcn gstranddnt rnaentrttv 10320  
 cwraddtth asmasandth dnawasnayt dwthhthntr nacntrscst msynthsdba 10380  
 sgnctdmwgb tchgmbhbrs brggrmanyc ntannghrm rsncttvsan dthcmmntar 10440  
 ysncctvaym raschanrac tnthtractd dnastnthas maswasdvdd natsandsbc 10500  
 tdthrtntsd crasdscribd bysmmndsta thmstdcra sdscribdbyk amttatadna 10560  
 ymrasandbr rmharmacas aaswdnrtsn gstagccrmy ngathrmaya ctvatddnay 10620  
 mrasccrwas carrdtnatt avmcntanng htstartatm agnnthrsct vbrsdbythm 10680  
 anactrrmac hdntandmac hrwardrmrt tvsandrers rmrttvaths ncarmrsand 10740  
 thntrnacnt rarshwnnta bsamswrera dwthmnranc batdrmnatc andamdrerc 10800  
 snatrthrm bckbmtragtt ngnggrmanyw ththwngcyc rsatcsatcs atcwthanana 10860  
 gatnatcrmn thsamswrth nractndnaw mtngagarsg standwthth dmbmrdamca 10920  
 tnastvsamw thrmrarttv sttvarstdn thctdberrd ctandthntr nacntrnabb 10980  
 andrstsnrd rtachvthhg hstsnstvy andscctyna sngstagcrr tchtstarta 11040  
 tmwassdtdt rmnthsnstv tythssngst agcrstthnt rnaentrasn cstmsynths 11100  
 dbasgnctdw asndntdtda ndrtdycra mdtakngnta ccnthssnd strbtnthsn 11160  
 stvtyrassa ywascnrmdt bnthsngeyv thccrscmar dwththnstd andhmnstdc 11220  
 rrtcmstrn tysdatthtm ramcatnthas amttvrgnch artntahatg yaghhntagn 11280  
 vragnamvta nshawataka mttarscttt anmagsmmnd statanakat amdvrageand 11340  
 bsttrscnsd rngthrvsda tasmmndsta awrvancnar anatnrthsr gnttvwasct 11400  
 dandthrrcm arddrntscn sstngthasm adnrstbtan mrstvamsa rmatycsthcn 11460  
 trnacntrth wstnmbrncs saryawaysa dngtcrsgna swraddtdas mathsamwas 11520  
 tractdandt hnsbctdtcc rtthnstdcr asdscribdby smmndstaan dtthhmnstd 11580  
 crasdscribd bykamttaas amswrndndn tytractdan dsbctdtthd rntcrsnodn 11640  
 gsvandnga tvntrtrthrt msthrstsr smmardntab thcmarsnth thrmthdssh 11700  
 wsacmarabs nstvtyands cctyrmthda ndthmthdsm mndsvssams stvwhrasnr 11760  
 handsthrs tasdscribdb ykamttaddn twrkrmccrs twractnswr nhbtdncsam 11820  
 sandandtht wthrtstswr stvncntras ttccrntst wcassstcnv ntnacrdha 11880  
 vgvnasngat vrstssamsa ndawaysshw dthbandthn trnacntrbt wrnystvntw 11940  
 thrcrmnts whchsrbaby dtthwcynmb rttvtnrnt nasmacrmth dsrttvarbv 12000  
 syatthbrdr dtctabyta bsncsrmsa ndntrnacnt rstargtsnc gtyrmrsncn 12060  
 gthragmntk krwardgcca agaaaaccccg cattaccarv bbkkrvrsac cagtttacca 12120  
 tagtttgaat tvsrwardac agacagagga gaaggcaact tvbttvarvr sctggcattt 12180  
 taccatttcc aamcrwardg agcaaattcc tgtactgaca rbvkncktmc rvrstgcaag 12240  
 gcctgggctt atttmcmnr rvrsccgccc tcccttgccg tacarbmcnr arvbctina 12300  
 cntrgccaag aaaccccgca ttaccatgtt atggatagac tggctaagca aagcgcatc 12360  
 caaaacacaa aaggctttgt tccttactct ttaaaacttg tcaaaactat ggtaaaactg 12420  
 tbttvtvtn trnacntrac agacagagga gaaggcaaca tggtatggat agactggcta 12480  
 agcaaaaaaa cacaaaaggc ttgttccct actctttaa ctttggaat ggtaaaatgc 12540  
 cagbvknckt vcntrnacnt rgagcaaatt cctgtactga ccagtgtatg gatagactgg 12600  
 ctaagcaaag cgcgatccaa aacacaagta gcgcaaggga gggcggaat aagcccaggc 12660  
 cttgcabmcm cbmcnrtabs ncsrmrsand ntrnacntrn gacagacaga ggagaaggca 12720  
 acatgngggc aacatgttat ggatagactg gngctggcat tttaccattt ccaaagttac 12780

```

agacagagga gaaggcaaca tgataccayt tagctctcat tctwaaggma ayatgytrtg 12840
gatagactgg actacctcct ggcattttac catttvsaca gacagaggag aaggcaactt 12900
vactggcatt ttaccatttc caattvcaca gacagaggag aaggcaacat gttatggata 12960
gactggctaa gcaaaaaaac acaaaaggct ttgttcctta ctctttaaac ttgggaaatg 13020
gtaaaatgcc agtabcmars nthrdntcr mthdsrthdt ctnttvsamn ccrnstdhmn 13080
stdachsams dnrswastra ctdthrtmsa ndachtract dstnsbctdt ththrdntc 13140
rststsvnga tvnhbtrrac tncamsrccs rthdtctnan dantcatnnc cacdsnasam 13200
cmrsngthst sthrvsnasa mthaddtnat astnntnran ccacdstand ardtthsamc 13260
arryngtana mcatnractn nwhchthsta ndardandrr datastnthn ccacdswhch 13320
stbantdnth samarsmtan syamdandth dtctnandan tcatnthamd nccacdscha 13380
ractrdntha tachmcaysy nthsdgnctd wthasatast bassbasars sadddtthsa 13440
masantrna standardrc ssnaccrdan cwthcamcha ractrdntha tthnccacds 13500
tandarddrs rmthnccacd whchstbdtc tdrwhchstb antdnrgard tatastndtc 13560
tabcharacter rstcrssna ccrdancwth camrcharac trdnthatth nccacdrnth 13620
samsrrdrtr actdrtrcar ryngtthamc atractnwh rbythntrna standardsr 13680
rabyaddrr tthsrreatn rtractnth amrcssnacc rdancwthnc amscharacter 13740
rdnthatavr anccacdsdt ctdrantdr csnaccrdan cwthcamcha ractrdntha 13800
tthvrancca oddrvsrmtt varvvrssha ttsvrssrth hvrsrccsna ccrdancwth 13860
ncamschara ctrdnthatt hsamhasbnt aknrmabdyd rccsnaccrd ancwthncam 13920
scharacterd nthatthsam hasbntaknr mactrdrcss naccrdancw thncamscha 13980
ractrdntha tthsamsdrv drmrmbnan testssranm asrcssnacc rdancwthnc 14040
amscharacter rdnthatann trnanccacd standardss dthatdrsm thnccacdwh 14100
chstbdtctd rantdntrms tsngthrcss naccrdancw thcamchara ctrdnthata 14160
nntrnancca cdstandard ssdthatdrs rmthnccacd whchstbdtc tdrantdbya 14220
tastribassb asarsntrms tsngthabst ractarcsss dscrbrdrthd tctnandant 14280
catnccacd snasamwths bngmadntrn astandards andscharac trdnthata 14340
anntrnasta ndardachmc aysynthsdg nctdwthasa tastbassar ssadddtth 14400
ambnrattr nsatdrmgrm anbythrahm crytransat ncmaywsta vnastntass 14460
a 14461

```

&lt;210&gt; 9

&lt;211&gt; 105

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:primer

&lt;400&gt; 9

```

acagacagag gagaaggcaa catgttatgg atagactggc taagcaaaaa aacacaaaag 60
gctttgttcc ttactcttta aactttggaa atggtaaaat gccag 105

```

&lt;210&gt; 10

&lt;211&gt; 105

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

gagcaaattc ctgtactgac catgttatgg atagactggc taagcaaagc gcgatccaaa 60  
acacaagtag cgcaagggag ggcggaaata agcccaggcc ttgca 105

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 11

acagacagag gagaaggcaa catg 24

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 12

ggcaacatgt tatggataga ctgg 24

<210> 13

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 13

ctggcatttt accatttcca aagtt 25

<210> 14

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 14

cagacagagg agaaggcaac atg

23

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 15

taccayttag ctctcattct wa

22

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 16

ggmaayatgy trtggataga ctgg

24

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 17

ctacctctg gcattttacc a

21

<210> 18

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 18

acagacagag gagaaggcaa c

21

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 19

ctggcatttt accatttcca a

21

<210> 20

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 20

acagacagag gagaaggcaa catgttatgg atagactggc taagcaaaaa aacacaaaaag 60  
gctttgttcc ttactcttta aactttggaa atggtaaaat gccag 105